CMS Rule Would Increase Cost Transparency of Medicaid-Covered Drugs.
JAMA
; 329(24): 2118, 2023 06 27.
Article
in En
| MEDLINE
| ID: mdl-37285174
Full text:
1
Collection:
01-internacional
Health context:
1_ASSA2030
Database:
MEDLINE
Main subject:
Centers for Medicare and Medicaid Services, U.S.
/
Medicare
/
Medicaid
/
Drug Costs
Type of study:
Health_economic_evaluation
Country/Region as subject:
America do norte
Language:
En
Journal:
JAMA
Year:
2023
Document type:
Article